Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$14.1 million.

  • Northwest Biotherapeutics' Free Cash Flow fell 6761.8% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.9 million, marking a year-over-year increase of 778.09%. This contributed to the annual value of -$58.0 million for FY2024, which is 167.68% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Free Cash Flow is -$14.1 million, which was down 6761.8% from -$7.0 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Free Cash Flow's 5-year high stood at -$7.0 million during Q2 2025, with a 5-year trough of -$20.3 million in Q4 2024.
  • In the last 5 years, Northwest Biotherapeutics' Free Cash Flow had a median value of -$12.8 million in 2021 and averaged -$12.9 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Free Cash Flow crashed by 8374.5% in 2022, and later surged by 5817.68% in 2025.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Free Cash Flow stood at -$12.8 million in 2021, then increased by 13.99% to -$11.0 million in 2022, then plummeted by 57.83% to -$17.4 million in 2023, then decreased by 16.59% to -$20.3 million in 2024, then skyrocketed by 30.43% to -$14.1 million in 2025.
  • Its last three reported values are -$14.1 million in Q3 2025, -$7.0 million for Q2 2025, and -$9.5 million during Q1 2025.